Citius Pharmaceuticals

CTXR · NASDAQ

$0.4175−$0.0103 (−2.41%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $0.4278

CTXR analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $4.08 (+877.2% upside)

Low: $4.04
Now: $0.4175
High: $4.20

Upgrades and downgrades

The latest rating actions, newest first

CTXR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	May 18, 2026	Initiates	Buy	$4.00	43%
D. Boral Capital	Mar 11, 2026	Maintains	Buy	$6.00	29%
D. Boral Capital	Dec 4, 2025	Maintains	Buy	$6.00	29%

The case for and against

Updated Sep 1, 2026

Bull case

Citius Pharmaceuticals is well-positioned for success as its cash and cash equivalents, along with additional funding and credit facilities, provide sufficient capital to fund operations through November 2026. Furthermore, the company's flagship product candidate, LYMPHIR, is projected to have a high initial price and an 88.5% royalty rate, potentially leading to profitability in FY2028. While risks such as commercial and regulatory hurdles exist, the recent strong efficacy signals from LYMPHIR in high-risk cancer patients support its potential for success.

Bear case

Citius Pharmaceuticals is a commercial-stage biopharmaceutical company, with a flagship product Lymphir approved for relapsed or refractory Stage I-III cutaneous T-cell lymphoma. While initial sales of Lymphir were promising, management attributes the sequential decline to initial stocking orders and the company's two late-stage candidates, Mino-Lok and Halo-Lido, are still pending regulatory filings due to financial constraints. Despite the potential for growth in revenue from Lymphir, the company's overall financial situation and lack of diversified product pipeline make it a risky investment for the short term, hence the negative outlook.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.